Compare MLSS & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLSS | ITRM |
|---|---|---|
| Founded | 1989 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9M | 24.3M |
| IPO Year | 1995 | 2018 |
| Metric | MLSS | ITRM |
|---|---|---|
| Price | $0.29 | $0.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $1.00 | ★ $9.00 |
| AVG Volume (30 Days) | 516.4K | ★ 1.1M |
| Earning Date | 11-13-2025 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,929,517.00 | $390,000.00 |
| Revenue This Year | $8.95 | N/A |
| Revenue Next Year | $7.51 | $193.01 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.59 | N/A |
| 52 Week Low | $0.23 | $0.26 |
| 52 Week High | $1.39 | $1.75 |
| Indicator | MLSS | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 42.98 | 44.82 |
| Support Level | $0.28 | $0.31 |
| Resistance Level | $0.30 | $0.35 |
| Average True Range (ATR) | 0.03 | 0.04 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 73.77 | 60.79 |
Milestone Scientific Inc is a biomedical technology company. The company is engaged in pioneering proprietary, technological systems and solutions for the medical and dental markets. The company develops, manufactures, markets, and sells the computer-controlled system for the improved and painless delivery of local anesthetics. The system is marketed in dentistry under the trademark CompuDent and in medicine under the trademark CompuMed. The Company conducts its business through two reportable segments: Dental and Medical.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.